Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies

This study tests LV009 injection — a CAR-T cell therapy that targets a protein called CD19 found on certain blood cancer cells — in people with relapsed or treatment-resistant non-Hodgkin lymphoma or acute lymphoblastic leukemia (a type of fast-growing blood cancer). **You may be eligible if...** - You are between 18 and 70 years old - You have confirmed CD19-positive non-Hodgkin lymphoma or acute lymphoblastic leukemia that has come back or not responded to treatment - Your cancer meets criteria for relapsed/refractory disease per standard guidelines - Your blood counts, liver, kidney, and heart-lung function are adequate - Your expected survival is more than 12 weeks **You may NOT be eligible if...** - Your cancer does not have the CD19 protein - Your blood counts or organ function are too low - You have had recent serious infections or other conditions preventing treatment Talk to your doctor to see if this trial is right for you.